



Published in final edited form as:

J Med Chem. 2011 September 8; 54(17): 6117–6124. doi:10.1021/jm200757g.

Identification and Biological Activities of New Taccalonolide Microtubule Stabilizers

Jiangnan Peng[†], April L. Risinger[†], Gary A. Fest[†], Evelyn M. Jackson[†], Gregory Helms[‡], Lisa A. Polin[§], and Susan L. Mooberry^{†,*}

[†]Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229

[‡]Nuclear Magnetic Resonance Center, Department of Chemistry, Washington State University, Pullman, WA 99164

[§]Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Department of Oncology, Detroit, MI 48201

Abstract

The taccalonolides are a unique class of microtubule stabilizers that do not bind directly to tubulin. Three new taccalonolides, Z, AA and AB, along with two known compounds, taccalonolides R and T, were isolated from *Tacca chantrieri* and *Tacca integrifolia*. Taccalonolide structures were determined by 1D and 2D NMR methods. The biological activities of the new taccalonolides, as well as taccalonolides A, B, E, N, R and T, were evaluated. All nine taccalonolides display microtubule stabilizing activity, but profound differences in antiproliferative potencies were noted, with IC₅₀ values ranging from the low nanomolar range for taccalonolide AA (32 nM) to the low micromolar range for taccalonolide R (13 μM). These studies demonstrate that diverse taccalonolides possess microtubule stabilizing properties and that significant structure-activity relationships exist. *In vivo* antitumor evaluations of taccalonolides A, E and N show that each of these molecules has *in vivo* antitumor activity.

Introduction

Microtubule stabilizers are one of the most important classes of anticancer therapeutics used in the clinic today. The taxoid microtubule stabilizer paclitaxel has been widely used in the treatment of solid tumors, including breast, ovarian and lung cancers for over a decade as a single agent and in combination with targeted therapies. In spite of their clinical utility, the shortcomings of paclitaxel and the second generation semi-synthetic taxoid, docetaxel, include innate and acquired drug resistance and dose limiting toxicities.¹ Two new microtubule stabilizers have been approved for clinical use in the past 3 years: the epothilone ixabepilone and the taxoid cabazitaxel, which circumvent some, but not all of the shortcomings of first and second generation microtubule stabilizers.^{2, 3} These microtubule stabilizing drugs all bind to the interior lumen of the intact microtubule at the taxoid binding site, which causes a stabilization of microtubule protofilament interactions and thereby decreases the dynamic nature of microtubules.⁴

*To whom correspondence should be addressed: Mooberry@uthscsa.edu. Pengj3@uthscsa.edu, Tel.: (210) 567-4788. Fax: (210) 567-4300.

Supporting Information Available: 1D and 2D NMR spectra of compound **5**, **6**, and **7**. This material is available free of charge via the Internet at <http://pubs.acs.org>

Two additional classes of microtubule stabilizers that do not bind within the taxoid site have been isolated from nature: laulimalides/peloruside A and the taccalonolides. Laulimalide and peloruside A have recently been shown to bind to the exterior of the microtubule at a site distinct from the taxoid binding site, but result in microtubule stabilization effects nearly identical to the taxoids.⁵ The taccalonolides are unique in that they do not bind directly to microtubules/tubulin and do not enhance the polymerization of purified tubulin in biochemical assays.⁶ The ability of the taccalonolides to cause microtubule stabilizing effects through a unique binding site and an entirely distinct mechanism of action prompted our interest in understanding this class of molecules.

Intense efforts over the past three decades have identified a large variety of interesting chemical compounds from the roots and rhizomes of *Tacca* species, including 25 taccalonolides, denoted as taccalonolides A – Y.^{7–15} However, there have been limited biological studies on the taccalonolides. In 2003, we first reported the microtubule stabilizing activities of taccalonolides A and E.¹⁶ Follow up studies showed preliminary structure-activity relationships (SAR) for the antiproliferative activities of taccalonolides A, E, B and N. The antiproliferative potencies of these 4 taccalonolides in HeLa cells were all in the mid nanomolar range (190 nM to 644 nM).¹⁷

In this study we isolated three previously undescribed taccalonolides designated: Z (**5**), AA (**6**) and AB (**7**). The biological activities of these molecules, as well as two previously isolated but biologically uncharacterized taccalonolides, R (**9**) and T (**8**) are presented. The mechanisms of action of all the taccalonolides were evaluated and compared to taccalonolides A and E. Each of these taccalonolides stabilizes cellular microtubules and causes mitotic accumulation of cancer cells with multiple abnormal mitotic spindles. The relative potencies of these taccalonolides range from 32 nM to 13 μ M, offering a broad range of activity that provides an opportunity to explore structure-activity relationships.

Results and Discussion

Taccalonolide isolation and structure elucidation

The roots and rhizomes of *T. chantrieri* and *T. integrifolia* were extracted using supercritical fluid CO₂ with methanol. After separation by flash chromatography using silica gel columns, normal and reverse phase HPLC was employed to obtain purified taccalonolides. Taccalonolides A (**1**), E (**3**), R (**9**), T (**8**), and AA (**6**) were isolated from *T. chantrieri*, while taccalonolide Z (**5**) was obtained from *T. integrifolia* (Figure 1). Mild base hydrolysis of taccalonolides A, E, and Z yielded taccalonolides B (**2**), N (**4**), and AB (**7**), respectively.

Taccalonolide Z (**5**) was obtained as a white powder. The proton NMR spectrum showed four acetyl signals at δ 2.16, 2.13, 2.00, 1.97, five methyl signals at δ 1.64 (s), 1.34 (s), 0.98 (s), 0.89 (d, $J = 7.2$ Hz), 0.73 (s), five oxygenated methine signals at δ 5.53 (t, $J = 10.2$ Hz), 5.23 (br), 5.22 (dd, $J = 9.6, 2.4$ Hz), 4.85 (d, $J = 5.4$ Hz), 4.73 (dd, $J = 10.2, 5.4$ Hz), two epoxy methine signals at δ 3.74 (t, $J = 4.5$ Hz) and 3.61 (dt, $J = 4.2, 1.8$ Hz), one olefinic signal at δ 5.06 (d, $J = 1.2$ Hz). All these proton NMR data are similar to those of taccalonolide A and indicated that **5** is a taccalonolide type steroid. The molecular formula of C₃₆H₄₆O₁₅ was determined by HRMS of 719.2934 (calc 719.2915), suggesting that **5** has one more oxygen than taccalonolide A (**1**). In addition, three signals for hydroxyl groups were observed at δ 3.64 (s), 3.45 (d, $J = 5.4$ Hz), and 2.58 (s), which is one more than taccalonolide A. The carbon-13 NMR showed 7 oxygenated carbon signals at δ 79.08, 78.74, 74.13, 74.06, 71.20, 71.17, 71.14, confirmed one more hydroxyl group for **5** as compared to taccalonolide A. The ³J HMBC correlation between the hydroxyl proton signal at δ 3.64 and the carbonyl carbon at δ 208.34 (C-6) suggested that the hydroxyl group is located at C-5. The configuration of this hydroxyl group was determined as α by the NOE

correlations between 5-OH/H-7,9,4 α . The other ^1H and ^{13}C NMR data for **5** is similar to those for **1**, thus, **5** was determined as 5 α -hydroxy-taccalonolide A and this was confirmed by 2D NMR data. A trivial name taccalonolide Z was given to **5** and its structure is shown in Figure 1.

Taccalonolide AA (**6**) was isolated as a white powder. The proton NMR spectrum of **6** showed characteristics almost identical to **5**, indicating a similar taccalonolide structure. Five acetyl signals at δ 2.20, 2.15, 2.14, 2.00, 1.98, five methyl signals at δ 1.64 (s), 1.34 (s), 1.04 (s), 0.91 (d, $J = 7.0$ Hz), 0.72 (s), five acetoxyated methine signals at δ 5.72(d, $J = 11.0$ Hz), 5.55 (d, $J = 9.5$ Hz), 5.25 (br), 5.23 (brd, $J = 11.0$ Hz), 4.91 (d, $J = 5.0$ Hz), two epoxy methine signals at δ 3.72 (t, $J = 4.5$ Hz) and 3.59 (br), one olefinic signal at δ 5.09 (br). Taccalonolide AA (**6**) has one more acetyl signal than taccalonolide Z (**5**). The chemical shift of H-7 at δ 5.72 (d, $J = 11.0$ Hz) was ca. 0.99 ppm down-field than that of **5**, suggesting this additional acetyl group was located at 7-OH. An HMBC correlation between H-7 and a carbonyl carbon at δ 170.8 confirmed this assignment. The other ^1H , ^{13}C and 2D NMR data are similar to **5**, thus, the structure of **6** was determined as shown in Figure 1 and a trivial name taccalonolide AA was assigned.

Taccalonolide AB (**7**) was obtained as white powder. The LC/MS showed pseudomolecular ions at 677 $[\text{M}+\text{H}]^+$, 694 $[\text{M}+\text{NH}_4]^+$, and 699 $[\text{M}+\text{Na}]^+$, indicating the loss of an acetyl group from taccalonolide Z (**5**). The proton NMR showed the chemical shift of H-15 of **7** at δ 4.75 (ddd, $J = 3.5, 9.0, 11.6$ Hz), which is shifted 0.78 ppm up-field than that of **5**, suggesting the loss of acetyl group at 15-OH. The HMBC correlation between 15-OH (δ 4.94) and C-15 (δ 71.5) confirmed the assignment.

Microtubule stabilization and mitotic arrest

The ability of the newly isolated taccalonolides to cause bundling of interphase microtubules was evaluated in HeLa cells. Consistent with the effects of taccalonolides A and E, which were shown to exert interphase microtubule bundling in previous studies,¹⁶ taccalonolides B, N, R, T, Z, AA and AB each caused the formation of thick bundled microtubule tufts typical of microtubule stabilizers including paclitaxel (Figure 2). Although microtubule stabilizers cause an increase in the density of interphase microtubules, the mechanism by which these agents inhibit the proliferation of cancer cells *in vitro* is widely accepted to be due to their ability to interrupt microtubule dynamics in mitosis, leading to mitotic arrest. The effect of the taccalonolides on mitotic progression was analyzed by flow cytometry. All nine taccalonolides caused an accumulation of cells in the G₂/M phase of the cell cycle with 4N DNA content (Figure 3). This accumulation is identical to the mitotic arrest that is observed after treatment of HeLa cells with paclitaxel (Figure 3).

The effects of the taccalonolides on mitotic spindle structures were evaluated to test whether they caused mitotic spindle defects leading to cell cycle arrest. β -tubulin and DNA were visualized in HeLa cells by indirect immunofluorescence and DAPI staining, respectively. The majority of cells treated with each taccalonolide at the concentration that caused G₂/M accumulation were found to be in mitosis as evidenced by a “rounded up” cellular morphology and condensed DNA. These mitotic cells contained multiple abnormal mitotic spindles, which is another common effect of microtubule stabilizing agents (Figure 4). These findings demonstrate that all nine taccalonolides, A, B, E, N, R, T, Z, AA and AB, are microtubule stabilizers that cause mitotic arrest of cells with multiple abnormal mitotic spindles.

Antiproliferative activities of the taccalonolides

The antiproliferative potencies of the taccalonolides were evaluated in HeLa cells using the SRB assay. The most potent taccalonolide is the newly identified taccalonolide AA, with an IC_{50} value of 32.3 nM (Table 1). This makes taccalonolide AA the most potent taccalonolide identified thus far. This low nanomolar potency is closer to other naturally occurring microtubule stabilizers, including paclitaxel, the epothilones, laulimalide and peloruside A, than the initially studied taccalonolides A and E.¹⁷ Other taccalonolides that had IC_{50} values in the nanomolar range include taccalonolides Z (120 nM), B (190 nM), N (247 nM), T (335 nM), A (594 nM) and E (644 nM) (Table 1). Taccalonolides AB and R were significantly less potent, with IC_{50} values of 2.8 μ M and 13.1 μ M, respectively (Table 1). The 400-fold difference in activity between the most and least potent taccalonolides isolated provides the opportunity to explore the structure-activity relationships among the taccalonolides.

Structure-activity of the taccalonolides

Our previous work comparing the potency of taccalonolides A, B, E and N in various drug sensitive and drug resistant cell lines gave a preliminary indication of the SAR of the taccalonolides, specifically the consequence of the presence or absence of an acetate group at C_{11} and/or C_{15} .¹⁷ Taccalonolides A and E differ only by the respective presence or absence of an acetoxy group at the C_{11} position and they did not show major differences in potency, suggesting that this acetoxy functionality did not influence potency or microtubule stabilizing activity. Similarly, taccalonolides B and N also differ from one another only by the presence or absence of an acetoxy group at C_{11} and showed comparable activity to one another. As evidenced by these 2 pairs of compounds, the presence or absence of the C_{11} acetoxy group did not have a large effect on potency.¹⁷ Another SAR evaluation made possible with these 2 pairs of compounds is the contribution of the C_{15} acetate. Taccalonolides B and N are produced by mild base hydrolysis of the C_{15} acetate of taccalonolides A and E respectively, resulting in a hydroxyl group at this position. A consistent increase in potency was observed upon hydrolysis of the C_{15} acetate as indicated by the 3.1-fold greater potency of taccalonolide B compared to A and the 2.6-fold greater potency of taccalonolide N compared to E in HeLa cells.¹⁷

We now expanded the number of taccalonolides available for SAR analysis from 4 to 9 by adding three new taccalonolides as well as two others that have not yet been evaluated for antiproliferative activities. Analysis of the potencies of these taccalonolides provided another opportunity to examine the effect of the C_{11} acetoxy group since the only difference between taccalonolides AA and R is the presence of this acetoxy substituent in taccalonolide AA. In contrast to the relative unimportance of the C_{11} acetoxy moiety on potency between the taccalonolides A and E or B and N, this modification caused a 400-fold difference in potency between taccalonolides AA and R (Table 1). The other structural differences between this new pair of taccalonolides and taccalonolides A, E, B, N occur in the southern part of the molecule where there is a hydroxyl group at C_5 and an acetate at 7-OH (Figure 1). Therefore, it appears that these structural features in the southern portion of taccalonolides AA and R confer sensitivities to the constituents present at C_{11} . These data suggest that interactions across the molecule can influence the potency of a taccalonolide.

Another indication that the individual chemical substituents on the taccalonolide backbone interact in a complex manner to influence activity is shown by the effects of hydrolysis of the C_{15} acetate. As mentioned above, when this acetate is hydrolyzed in taccalonolides A or E, the resulting products, taccalonolides B and N, show a 2.6 to 3.1-fold increase in potency (Table 1).¹⁷ However, when this same acetate is hydrolyzed in taccalonolide Z to yield taccalonolide AB, the potency is decreased by 23-fold (Table 1). Again, context is

important, because the only difference between taccalonolides Z and A is a hydroxyl group at the C₅ position (Figure 1). Finally, taccalonolide T is unique from the other taccalonolides evaluated in this study in that it contains a bulky isovalerate substituent at the C₁ position (Figure 1). This is the only difference between taccalonolides R and T and provides a dramatic 38-fold increase in potency (Table 1). It will be interesting to see whether adding steric bulk at this position has a consistent effect on potency in further studies.

These findings strongly suggest that the SAR for the taccalonolides is not simple and instead suggests that there are complex relationships among multiple sites on the taccalonolide backbone. Based on the limited data with these taccalonolides, we can categorize the taccalonolides into two groups, those with the 5-hydroxy group and those without the 5-hydroxy group. For taccalonolides without 5-hydroxyl group, which include the taccalonolides A, B, E, and N, hydrolysis of the C₁₅ acetate resulted in 2~3 fold increase in potency, and the C₁₁ acetoxy group did not affect the activity. For taccalonolides with the 5-hydroxyl group, taccalonolides Z, AA, AB, T and R, the presence of the C₁₁ acetoxy group dramatically increased the activity (taccalonolide AA vs. R), while hydrolysis of the C₁₅ acetate decreased the activity (taccalonolide Z vs. AB). Finally, adding bulk to the acetate at C₁ also increased potency (taccalonolide T vs. R). Although there does not appear to be a clear link between potency and any particular chemical substituent on the taccalonolide backbone, these data highlight the importance of isolating additional taccalonolides and making directed chemical modifications to further probe the complex interactions across the molecule. In future studies we will probe the effects of introducing different bulky groups on C₁ together with acetoxy groups at C₁₁ to find the best combination of substituents at these sites. For example, the addition of a bulky substituent at the C₁ of taccalonolide AA may further improve the potency. Other studies planned will further evaluate the roles of the different acetylating groups at C₇ and C₁₅.

***In vivo* antitumor activity**

Antitumor studies were conducted to evaluate the *in vivo* activity of taccalonolides A, E and N. This evaluation is important since *in vitro* activity is not necessarily retained *in vivo* because of pharmacokinetic properties and drug metabolism. The syngeneic murine mammary carcinoma 16/C model was used because it is an incurable, rapidly growing tumor that provides a rigorous test of new agents.^{18, 19} A total dose of 73.5 mg/kg paclitaxel was used as a positive control and, as expected, it provided excellent antitumor effects with a 0% T/C, 19 day tumor growth delay (T-C) and 4.8 gross log cell kill (Table 2). In comparison, a total dose of 56 mg/kg taccalonolide A provided excellent antitumor activity with a 0% T/C, 16 day tumor growth delay (T-C) and 4.0 gross log cell kill (Table 2). However, with this dose and schedule, taccalonolide A also produced a 16.7% mean body weight loss and delayed toxicity with one lethality occurring 16 days after the final dose was administered. A lower dose of taccalonolide A (40 mg/kg total) was better tolerated but less effective, yielding a 24% T/C and 1.0 gross log cell kill (Table 2).

Taccalonolide E at a total dose of 90 mg/kg provided a 17% T/C and 1.25 gross log cell kill with a well-tolerated maximal 4.1% body weight loss. At a lower total dose of 54 mg/kg, taccalonolide E yielded an 81% T/C. Similarly, taccalonolide N at a total dose of 36 mg/kg generated a T/C of 0% and a 1.25 gross log cell kill while the 20 mg/kg total dose was less effective with a T/C of 43% and a 0.25 gross log cell kill (Table 2). These data indicate that 56 mg/kg taccalonolide A provided the longest tumor growth delay (T-C) and the highest gross log cell kill of the taccalonolides tested in this trial. However, at this dose taccalonolide A was above the maximum tolerated dose (MTD) because it caused substantial weight loss and 20% lethality. Antitumor effects at doses over the MTD are difficult to interpret because they cannot be clearly separated from the toxic effects on the whole animal. However, a slightly lower total dose of taccalonolide A, 40 mg/kg, showed antitumor activity with low

toxicity (Table 2). Additionally, in a previous study a 38 mg/kg total dose of taccalonolide A was highly effective against a drug resistant tumor, and caused no drug deaths¹⁷, suggesting that taccalonolide A has a narrow therapeutic window. At the highest non-toxic doses tested, all the taccalonolides showed comparable antitumor activity, suggesting that the core structure of this class of molecules possesses antitumor activity that may be amenable to refinement and improvement through the isolation of additional taccalonolides and/or analog development. Pharmacokinetic and metabolism studies are planned for the future to further understand the factors that affect *in vivo* efficacy of the taccalonolides.

Experimental Section

Chemistry

NMR spectra were recorded on a Bruker Avance 500, 600 or 700 MHz instrument equipped with cryo Probe and a Varian VNMRs 600 MHz instrument. All spectra were measured and reported in ppm using the residual solvent (CDCl₃) as an internal standard. The HRMS was measured using a Thermo Scientific LTQ Orbitrap mass spectrometer. IR data were obtained on a Bruker Vector 22 with a Specac Golden Gate ATR sampler. The UV spectra were measured on a Varian Cary 5000 UV-Vis NIR spectrophotometer. TLC was performed on aluminum sheets (silica gel 60 F₂₅₄, Merck KGaA, Germany). HPLC was performed on a Waters Breeze HPLC system. LC/MS was conducted on a Waters Alliance 2695 HPLC module, 996 photodiode array detector, and Micromass Quattro triple quadrupole mass spectrometer equipped with ESI. The purities of all compounds were determined to be greater than 95% by LC/MS and NMR.

Plant material

Tacca chantriери and *T. integrifolia* plants were purchased from a commercial grower. The roots and rhizomes were collected from living plants and stored at -80 °C until lyophilized.

Extraction and isolation of the taccalonolides

Dried and pulverized rhizomes (2.3 kilogram) of *T. chantriери* were extracted in several batches using supercritical CO₂ with MeOH. The crude extracts were washed with hexanes and extracted with CH₂Cl₂. The CH₂Cl₂ extracts were subjected to silica gel flash chromatography and eluted with hexanes:isopropanol (82:18) to obtain the taccalonolide enriched fraction. This fraction (1.4 g) was further purified on a silica gel HPLC column and eluted with isooctane:isopropanol (81:19) to yield fractions 1–8. Taccalonolides A (**1**) and E (**3**) were obtained from fractions 2 and 4 respectively. Fraction-1 (33 mg) was separated on a C-18 HPLC column, eluting with a gradient of acetonitrile:H₂O from 30% to 80% over 40 minutes, to yield 1.2 mg of taccalonolide AA (**6**) and 0.8 mg of taccalonolide T (**8**). Fraction-3 was purified on silica gel flash column and eluted with CH₂Cl₂:acetone 85:15 to yield taccalonolide R (**9**).

The roots and rhizomes of *T. integrifolia* (1445 g) were extracted to yield 11.7 grams of CH₂Cl₂ extract using the same method as *T. chantriери*. The CH₂Cl₂ extract was purified by silica gel flash chromatograph followed by repeated normal phase HPLC to yield 13.1 mg of taccalonolide Z (**5**).

Hydrolysis of the taccalonolides

Taccalonolide A (40 mg) was dissolved in 4 mL of methanol and to this solution 8 mL of 0.05 M sodium bicarbonate was added. The solution was stirred at room temperature for 44 hours. The reaction solution was extracted with EtOAc and purified on HPLC to yield 25.8 mg of taccalonolide B (**2**). Taccalonolides N (**4**) and AB (**7**) were produced by hydrolysis of taccalonolides E (**3**) and Z (**5**), respectively, using the same method.

Taccalonolide Z (**5**): white powder; HRESIMS: m/z 719.2934 (calcd for $C_{36}H_{47}O_{15}$ 719.2915); ESIMS: m/z 719.4 $[M+H]^+$, 736.4 $[M+NH_4]^+$, 731.5 $[M+Na]^+$; 1H NMR: δ (ppm) 5.53 (t, $J = 9.8$ Hz, H-15), 5.23 (br., H-12), 5.22 (dd, $J = 9.6, 2.4$ Hz, H-11), 5.06 (d, $J = 1.5$ Hz, H-22), 4.85 (d, $J = 5.4$ Hz, H-1), 4.73 (dd, $J = 10.2, 5.1$ Hz, H-7), 3.74 (t, $J = 4.5$ Hz, H-2), 3.64 (s, 5-OH), 3.61 (m, H-3), 3.45 (d, $J = 5.2$ Hz, 7-OH), 3.17 (t, $J = 11.6$ Hz, H-9), 2.58 (s, 25-OH), 2.57 (dd, $J = 15.0, 1.6$ Hz, H-4a), 2.52 (t, $J = 10.1$ Hz, H-14), 2.42 (dd, $J = 13.4, 10.2$ Hz, H-16), 2.23 (d, $J = 16.7$ Hz, H-4b), 2.16 (s, 3H, 1-OAc), 2.15 (m, H-20), 2.13 (s, 3H, 12-OAc), 2.00 (s, 3H, 15-OAc), 1.97 (s, 3H, 11-OAc), 1.81 (dd, $J = 13.4, 9.8$ Hz, H-17), 1.64 (s, 3H, H-27), 1.56 (q, $J = 10.8$ Hz, H-8), 1.34 (s, 3H, H-28), 0.98 (s, 3H, H-18), 0.89 (d, 3H, $J = 7.2$ Hz, H-21), 0.73 (s, 3H, H-19); ^{13}C NMR: δ (ppm) 208.34 (C-6), 178.10 (C-26), 172.07 (15-OAc), 170.85 (11-OAc), 169.40(1-OAc), 169.25 (12-OAc), 154.50 (C-23), 111.07 (C-22), 79.08 (C-5), 78.74 (C-25), 74.13 (C-12), 74.06 (C-1), 71.20 (C-15), 71.17 (C-7), 71.14 (C-11), 54.16 (C-14), 54.06 (C-3), 50.97 (C-16), 50.60 (C-2), 50.07 (C-24), 48.85 (C-17), 45.86 (C-10), 44.19 (C-8), 43.15 (C-13), 37.13 (C-9), 30.61 (C-20), 26.94 (C-4), 25.32 (C-28), 22.36 (15-OAc), 21.16 (11-OAc), 21.02 (12-OAc), 20.72 (1-OAc), 20.61 (C-27), 20.08 (C-21), 14.61 (C-19), 13.37 (C-18).

Taccalonolide AA (**6**): white powder; HRESIMS: m/z 761.3032 (calcd for $C_{38}H_{49}O_{16}$ 761.3021); ESIMS: m/z 761.4 $[M+H]^+$, 778.4 $[M+NH_4]^+$, 783.5 $[M+Na]^+$, 701.3 $[M-OAc]^+$; 1H NMR: δ (ppm) 5.73 (d, $J = 11.0$ Hz, H-7), 5.55 (t, $J = 9.4$ Hz, H-15), 5.25 (d, $J = 2.6$ Hz, H-12), 5.23(dd, $J = 11.7, 2.6$ Hz, H-11), 5.09 (d, $J = 1.4$ Hz, H-21), 4.91 (d, $J = 5.5$ Hz, H-1), 3.72 (t, $J = 4.5$ Hz, H-2), 3.61 (s, 5-OH), 3.59 (m, H-3), 3.30 (t, $J = 11.4$ Hz, H-9), 2.63 (t, $J = 10.0$ Hz, H-14), 2.62 (s, 25-OH), 2.56 (brd, $J = 14.5$ Hz, H-4a), 2.43 (dd, $J = 13.4, 9.8$ Hz, H-16), 2.20 (s, 3H, 1-OAc), 2.19 (m, H-4b), 2.17 (m, H-20), 2.16 (s, 3H, 11-OAc), 2.15 (s, 3H, 12-OAc), 2.03 (q, $J = 11.0$ Hz, H-8), 2.00 (s, 3H, 7-OAc), 1.98 (s, 3H, 15-OAc), 1.65 (s, 3H, H-27), 1.33 (s, 3H, H-28), 1.04 (s, 3H, H-18), 0.92 (s, 3H, H-21), 0.73(s, 3H, H-18); ^{13}C NMR: δ (ppm) 201.65 (C-6), 178.04 (C-25), 172.10 (15-OAc), 170.88 (11-OAc), 170.76 (7-OAc),, 169.51 (1-OAc), 169.33(12-OAc), 154.34 (C-23), 111.33 (C-22), 79.76 (C-5), 79.10 (C-26), 74.31 (C-7), 74.26 (C-1), 73.99 (C-12), 71.54 (11), 71.22 (C-15), 54.34 (14), 54.22 (C-3), 51.60 (C-16), 50.60 (C-2), 50.26 (C-24), 48.66 (C-17), 45.64 (C-10), 43.61 (C-13), 39.48 (C-8), 38.57 (C-9), 30.75 (C-20), 26.78 (C-4), 25.37 (C-28), 22.79 (15-OAc), 21.27 (7-OAc), 21.23 (12-OAc), 21.19 (11-OAc), 20.97 (1-OAc), 20.68 (C-21), 20.21 (C-27), 14.88 (C-19), 13.74 (C-18).

Taccalonolide AB (**7**): white powder; HRESIMS: m/z 677.2814 (calcd for $C_{34}H_{45}O_{14}$ 677.2809); ESIMS: 677.4 $[M+H]^+$, 694.4 $[M+NH_4]^+$, and 699.4 $[M+Na]^+$. 1H NMR: δ (ppm) 5.27 (dd, $J = 11.9, 2.1$ Hz, H-11), 5.22 (d, $J = 2.1$ Hz, H-12), 5.01 (br., H-21), 4.93 (d, $J = 3.6$ Hz, 15-OH), 4.91 (dd, $J = 10.8, 4.6$ Hz, H-7), 4.83 (d, $J = 5.4$ Hz, H-1), 4.62 (br, 25-OH), 4.47 (ddd, $J = 11.1, 9.0, 3.4$ Hz, H-15), 4.05 (d, $J = 4.5$ Hz, 7-OH), 3.76 (t, $J = 4.5$ Hz, H-2), 3.69 (s, 5-OH), 3.63 (m, H-3), 3.17 (t, $J = 11.6$ Hz, H-9), 2.56 (brd, $J = 15.7$ Hz, H-4a), 2.43 (dd, $J = 13.0, 11.0$ Hz, H-16), 2.26 (m, $J = 16.8$ Hz, H-4b), 2.24 (m, H-14), 2.17 (s, 3H, 1-OAc), 2.15 (m, H-20), 2.14 (s, 3H, 12-OAc), 1.99 (s, 3H, 11-OAc), 1.86 (dd, $J = 13.2, 9.9$ Hz, H-17), 1.69 (s, 3H, H-27), 1.64 (q, $J = 10.9$ Hz, H-8), 1.37 (s, 3H, H-28), 0.97 (s, 3H, H-18), 0.89 (d, 3H, $J = 7.0$ Hz, H-21), 0.78 (s, 3H, H-19); ^{13}C NMR: δ (ppm) 207.23 (C-6), 175.35 (C-26), 171.12 (12-OAc), 169.64 9 (1-OAc), 169.51 (12-OAc), 154.90 (C-22), 110.43 (C-21), 79.10 (C-25), 78.75 (C-5), 74.41 (C-12), 74.12 (C-1), 72.04 (C-7), 71.46 (C-15), 70.89 (C-11), 57.57 (C-14), 54.12 (C-3), 51.04 (C-24), 50.79 (C-2), 50.28 (C-16), 48.19 (C-17), 46.06 (C-10), 44.06 (C-14), 43.82 (C-8), 36.66 (C-9), 31.17 (C-20), 27.07 (C-4), 25.62 (C-28), 21.99 (C-27), 21.35 (12-OAc), 21.14 (11-OAc), 20.83 (1-OAc), 20.30 (C-21), 14.70 (C-19), 13.44 (C-18).

Cell culture

The HeLa cervical cancer cell line was obtained from American Type Tissue Culture Collection (Manassas, VA) and grown in Basal Media Eagle (BME) medium (Invitrogen; Carlsbad, CA) supplemented with 10% fetal bovine serum (Hyclone; Logan, UT) and 50 µg/ml gentamicin sulfate (Invitrogen).

Inhibition of cellular proliferation

The antiproliferative effects of the taccalonolides were evaluated using the SRB assay²⁰ as previously described.¹⁶ The concentration of drug that causes a 50% inhibition of cellular proliferation (IC₅₀) was calculated from the linear portion of the log dose response curve. Each IC₅₀ value represents the mean and standard deviation of 3–5 independent experiments, each performed in triplicate. Paclitaxel is included as a reference compound. The determination of IC₅₀ values was performed on taccalonolide material after NMR analysis and subsequent lyophilization. Ethanol was used as the vehicle for all cellular studies.

Immunofluorescence

Cellular microtubules in interphase or mitotic HeLa cells were visualized using indirect immunofluorescence techniques as previously described.¹⁶ Cells were treated for 18 h with vehicle, a taccalonolide or the positive control paclitaxel, fixed with methanol and microtubules visualized with a β-tubulin antibody. Representative images of interphase and mitotic cells were acquired using a Nikon Eclipse 80i fluorescence microscope and compiled using NIS Elements AR 3.0 software. Concentrations of taccalonolides that caused similar levels of mitotic arrest at 18 h were used (5 – 10x their IC₅₀ values). Paclitaxel requires a substantially higher concentration, 400x the IC₅₀, to initiate interphase bundling.

Flow cytometry

HeLa cells were incubated for 18 h with vehicle, each taccalonolide or paclitaxel as a positive control. The cells were harvested and the DNA was stained with propidium iodide using Krishan's reagent.²¹ Cellular DNA content was analyzed using a FACS Calibur flow cytometer (BD Biosciences). Data were plotted as propidium iodide intensity versus the number of events using ModFit LT 3.0 software (Verity Software, Topsham, ME). Concentrations of paclitaxel or taccalonolide that caused similar levels of mitotic arrest at 18 h were used (5 – 10x their IC₅₀ values).

In vivo testing

The antitumor efficacies of taccalonolides A, E and N were evaluated in the murine syngeneic Mammary 16/C model.¹⁸ The average mouse weight was 19.3 ± 1.0 g at the start of treatment. Tumor fragments were bilaterally implanted subcutaneously in female B₆C₃F₁ (C57BL6 × C3H) mice on day 0, then non-selectively distributed to the various treatment and control groups (n = 5 mice/group). All drugs were administered by IV in a 0.2 ml volume. The taccalonolides were solubilized in 50% DMSO:50% Cremophor to generate stocks of 10.0–12.1 mg/ml and then diluted with sterile water for injections. Paclitaxel (Mayne Pharma; Salisbury South, SA) was diluted with water from clinical grade stocks to a final concentration of 6 mg/mL.

The protocol design and antitumor efficacy analyses were performed as described previously.¹⁹ The scheduling was based on our prior studies to optimize antitumor activity and reduce toxicity. Each taccalonolide was administered intravenously on days 1, 4 and 6 with an additional dose 2–3 days later for taccalonolides A and N. Taccalonolide E treatments were also administered on days 8, 9 and 11 because the weight loss was least

severe in this treatment group. Mice were weighed and observed daily and tumor size measured 2 to 3 times weekly. Tumor mass was calculated using the formula: mass (mg) = length (mm) × width (mm)² / 2. Antitumor efficacy was evaluated by the following standard calculations: 1) %T/C: The median tumor mass of a given treated group (T) divided by the median tumor mass of the control (C), expressed as percent. The %T/C determination includes “zeros” and is made when the control group tumors reach exponential growth at approximately 700 – 1200 mg in size; 2) Tumor growth delay (T-C) and tumor cell kill: These measurements are quantitative determinations of antitumor activity. (T-C) is the median number of days between the time the treatment (T) and control (C) group tumors reach the pre-determined size of 1000 mg. Tumor free survivors are excluded from this calculation and are tabulated separately. Tumor cell kill is determined using tumor growth delay (T-C) as described above in the formula: gross log cell kill = (T-C)/3.32 * (Td), where Td is the tumor volume doubling time (in days) estimated from the best fit straight line from a log-linear growth plot of control group tumors in exponential growth phase.

The mice were purchased from the NCI-Frederick Animal Production Program (Frederick, MD), housed in an AALAC-approved facility under fully licensed veterinary care (Wayne State University, Detroit, MI) and provided water and food *ad libitum*.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Abbreviations list

HSQC	heteronuclear single-quantum coherence
HMBC	heteronuclear multi-bond correlation spectroscopy
SAR	Structure-activity relationship

Acknowledgments

This work was supported by NCI CA121138 (SLM), DOD-CDMRP Postdoctoral Award BC087466 (ALR), and the NCI P30 CA054174 (SLM).

References

1. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2007; 18 Suppl 5:v3–v8. [PubMed: 17656560]
2. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2008; 14:7167–7172. [PubMed: 19010832]
3. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. *Nature reviews. Drug discovery*. 2010; 9:677–678.
4. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5 Å and location of the taxol-binding site. *Nature*. 1995; 375:424–427. [PubMed: 7760939]
5. Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. *Chem Biol*. 2010; 17:725–734. [PubMed: 20659685]
6. Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu JM, Diaz JF. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. *Chem Biol*. 2005; 12:1269–1279. [PubMed: 16356844]

7. Chen Z, Wang B, Chen M. Steroidal bitter principles from *tacca plantaginea* structures of taccalonolide A and B. *Tetrahedron Letters*. 1987; 28:1673–1676.
8. Chen Z, Wang B, Shen J. Taccalonolide C and D, two pentacyclic steroids of *Tacca plantaginea*. *Phytochemistry*. 1988; 27:2999–3002.
9. Shen J, Chen Z, Gao Y. The pentacyclic steroidal constituents of *Tacca plantaginea*: taccalonolides E and F. *Chinese journal of chemistry*. 1991; 9:92–94.
10. Shen J, Chen Z, Gao Y. Taccalonolides from *Tacca plantaginea*. *Phytochemistry*. 1996; 42:891–893.
11. Chen Z, Shen J, Gao Y, Wichtl M. Five taccalonolides from *Tacca plantaginea*. *Planta Medica*. 1997; 63:40–43. [PubMed: 17252326]
12. Muhlbauer A, Gehling M, Velten R, Andersch W, Erdelen C, Harder A, Marczok P, Nauen R, Turberg A, Tran VS, Adam G, Liu J. Isolation and preparation of taccalonolides for controlling animal pests . 2001. PCT Int. Appl. 2001 WO2001040256 A1 20010607.
13. Huang Y, Liu J. Three novel taccalonolides from the tropical plant *Tacca subflaellata*. *Helvetica Chimica Acta*. 2002; 85:2553–2558.
14. Muhlbauer A, Seip S. Five novel taccalonolides from the roots of the vietnamese plant *Tacca paxiana*. *Helvetica Chimica Acta*. 2003; 86:2065–2072.
15. Yang J, Zhao R, Chen C, Ni W, Teng F, Hao X, Liu H. Taccalonolides W-Y, three new pentacyclic steroids from *Tacca plantaginea*. *Helvetica Chimica Acta*. 2008; 91:1077–1082.
16. Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC Jr, Hemscheidt TK, Mooberry SL. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity. *Cancer Res*. 2003; 63:3211–3220. [PubMed: 12810650]
17. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Luduena RF, Kruh GD, Mooberry SL. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. *Cancer Res*. 2008; 68:8881–8888. [PubMed: 18974132]
18. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. *Cancer treatment reports*. 1978; 62:1471–1488. [PubMed: 709550]
19. Polin, L.; Corbett, T.; Roberts, BJ.; Lawson, AJ.; Leopold, WR., III; White, K.; Kushner, J.; Paluch, J.; Hazeldine, S.; Moore, R.; Rake, J.; Horwitz, JP. *Transplantable Syngeneic Rodent Tumors: Solid Tumors of Mice*. 2nd ed. Totowa, NJ: Humana Press Inc.; 2011. p. 43-78.
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst*. 1990; 82:1107–1112. [PubMed: 2359136]
21. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. *J Cell Biol*. 1975; 66:188–193. [PubMed: 49354]




Figure 1.
Structures of the taccalonolides.




Figure 2. Effect of the taccalonolides on interphase cells. HeLa cells were treated for 18 h with vehicle (A), 0.5 μM paclitaxel (B), 3.5 μM taccalonolide A (C), 0.8 μM taccalonolide B (D), 2.5 μM taccalonolide E (E), 1.3 μM taccalonolide N (F), 57 μM taccalonolide R (G), 3.5 μM taccalonolide T (H), 0.6 μM taccalonolide Z (I), 0.32 μM taccalonolide AA (J) or 13.5 μM taccalonolide AB (K). Interphase microtubule structures were visualized by indirect immunofluorescence using a β -tubulin antibody.




Figure 3.

Effect of the taccalonolides on cell cycle distribution. HeLa cells were treated with vehicle (A), 12 nM paclitaxel (B), 3.5 μ M taccalonolide A (C), 0.8 μ M taccalonolide B (D), 2.5 μ M taccalonolide E (E), 1.3 μ M taccalonolide N (F), 111 μ M taccalonolide R (G), 3.5 μ M taccalonolide T (H), 0.6 μ M taccalonolide Z (I), 0.32 μ M taccalonolide AA (J) or 13.5 μ M taccalonolide AB (K) for 18 h and stained with Kirshan's reagent. Open and filled arrowheads denote the populations of cells with 2N (G_1) and 4N (G_2/M) DNA content, respectively.




Figure 4. Effect of the taccalonolides on mitotic spindles. HeLa cells were treated for 18 h with vehicle (A), 12 nM paclitaxel (B), 3.5 μM taccalonolide A (C), 0.8 μM taccalonolide B (D), 2.5 μM taccalonolide E (E), 1.3 μM taccalonolide N (F), 57 μM taccalonolide R (G), 3.5 μM taccalonolide T (H), 0.6 μM taccalonolide Z (I), 0.32 μM taccalonolide AA (J) or 13.5 μM taccalonolide AB (K). The microtubule structures in mitotic cells were visualized by indirect immunofluorescence using a β -tubulin antibody.

Table 1

Antiproliferative potency of taccalonolides

Taccalonolide	IC₅₀ (nM)
Taccalonolide A	594 ± 43
Taccalonolide B	190 ± 3
Taccalonolide E	644 ± 10
Taccalonolide N	247 ± 16
Taccalonolide R	13,144 ± 1,390
Taccalonolide T	335 ± 24
Taccalonolide Z	120 ± 7.5
Taccalonolide AA	32.3 ± 1.9
Taccalonolide AB	2,767 ± 107
Paclitaxel	1.2 ± 0.1

The concentration of each drug that causes 50% inhibition of cellular proliferation (IC₅₀) after 48 h treatment was measured using the SRB assay (n=3–5).

IC₅₀ values for taccalonolides A, E, B and N are from Risinger et al., 2008¹⁷.

Table 2

Antitumor effects of taccalonolides A, E, and N in the Mammary 16/C model.

Treatment	Total dose (mg/kg)	T/C (%)	T-C (days)	Gross log cell kill	Median (range) of tumor size and number of tumor-free mice on day 12	Mean body weight loss (%)
No treatment	-	-	-	-	1029 (63–2827)	-2.2
Paclitaxel	73.5	0	19	4.8	0 (all zero)	-6.3
Taccalonolide A	56	0	16	4.0	0 (all zero)	-16.7*
Taccalonolide A	40	24	4	1.0	256 (108–756)	-6.3
Taccalonolide E	90	17	5	1.25	172 (0–947) 1/5 = 0	-4.1
Taccalonolide E	54	81	1	0.25	837 (0–1755) 1/5 = 0	-2.0
Taccalonolide N	36	0	5	1.25	(0–126) 3/5 = 0	-8.2
Taccalonolide N	20	43	1	0.25	445 (0–2277) 1/5 = 0	-2.1

T/C is the median tumor mass of a given treated group (T) divided by the median tumor mass of the control (C) and expressed as a percent. The tumor growth delay (T-C) is the median number of days between the time the treatment (T) and control (C) group tumors reach the pre-determined size of 1000 mg. The gross log cell kill is calculated by $(T-C)/3.32 \times (Td)$, where Td is the tumor volume doubling time (in days).

* A 20% lethality (1/5 mice) was observed at this dose.